Locametz is a drug owned by Novartis Pharmaceuticals Corp. It is protected by 2 US drug patents filed from 2022 to 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 09, 2036. Details of Locametz's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US11369590 | PSMA binding ligand-linker conjugates and methods for using |
Aug, 2028
(3 years from now) | Active |
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US12109277 | NA |
Mar, 2036
(11 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Locametz's patents.
Latest Legal Activities on Locametz's Patents
Given below is the list of recent legal activities going on the following patents of Locametz.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Patent Issue Date Used in PTA Calculation Critical | 28 Jun, 2022 | US11369590 |
| Recordation of Patent Grant Mailed Critical | 28 Jun, 2022 | US11369590 |
| Email Notification Critical | 09 Jun, 2022 | US11369590 |
| Issue Notification Mailed Critical | 08 Jun, 2022 | US11369590 |
| Dispatch to FDC | 31 May, 2022 | US11369590 |
| Application Is Considered Ready for Issue Critical | 31 May, 2022 | US11369590 |
| Electronic Review Critical | 20 Apr, 2022 | US11369590 |
| Issue Fee Payment Verified Critical | 20 Apr, 2022 | US11369590 |
| Email Notification Critical | 20 Apr, 2022 | US11369590 |
| Issue Fee Payment Received Critical | 20 Apr, 2022 | US11369590 |
FDA has granted several exclusivities to Locametz. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Locametz, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Locametz.
Exclusivity Information
Locametz holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2025. Details of Locametz's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 23, 2025 |
Several oppositions have been filed on Locametz's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Locametz's generic, the next section provides detailed information on ongoing and past EP oppositions related to Locametz patents.
Locametz's Oppositions Filed in EPO
Locametz has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jul 07, 2020, by Boult Wade Tennant Llp. This opposition was filed on patent number EP08798020A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP08798020A | Jul, 2020 | Orano Med | Revoked |
| EP08798020A | Jul, 2020 | Boult Wade Tennant LLP | Revoked |
US patents provide insights into the exclusivity only within the United States, but Locametz is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Locametz's family patents as well as insights into ongoing legal events on those patents.
Locametz's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Locametz's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Mar 09, 2036 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Locametz Generics:
There are no approved generic versions for Locametz as of now.
Alternative Brands for Locametz
Locametz which is used for detecting prostate cancer lesions in men through positron emission tomography after radiolabeling with gallium-68., has several other brand drugs using the same active ingredient (Gallium Ga-68 Gozetotide). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Telix |
|
About Locametz
Locametz is a drug owned by Novartis Pharmaceuticals Corp. It is used for detecting prostate cancer lesions in men through positron emission tomography after radiolabeling with gallium-68. Locametz uses Gallium Ga-68 Gozetotide as an active ingredient. Locametz was launched by Novartis in 2022.
Approval Date:
Locametz was approved by FDA for market use on 23 March, 2022.
Active Ingredient:
Locametz uses Gallium Ga-68 Gozetotide as the active ingredient. Check out other Drugs and Companies using Gallium Ga-68 Gozetotide ingredient
Treatment:
Locametz is used for detecting prostate cancer lesions in men through positron emission tomography after radiolabeling with gallium-68.
Dosage:
Locametz is available in powder form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| N/A | POWDER | Prescription | INTRAVENOUS |